Back to discover
Drug

Sebetralstat

Approved · EMA

Also known as Ekterly.

RxNorm2717944ChEMBLCHEMBL5095248UNIIO5ZD2TU2B7
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Approval: Ekterly (EMA)

Regulatory2025-09-17EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Sebetralstat
Aliases & brands
Ekterly
RxNorm CUI
2717944
ChEMBL ID
CHEMBL5095248
UNII
O5ZD2TU2B7
Regulatory jurisdictions
ema

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2025-09-17
Latest approval
2025-09-17
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2025-09-17Approval
Approval: Ekterly (EMA)

Indication: Ekterly is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. 

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Regulatory event sources are credited in the Regulatory Timeline above.